Roche Holding AG
RHHVF
Market Cap$242.7B
Close$
Earnings Call Q2 2024
July 25, 2024 - AI Summary
Group sales increased by 8% in the first half of the year, excluding COVID impact.
Pharma division saw strong growth in base business with an 8% increase in sales.
Diagnostics division also experienced solid growth with a 9% increase in sales.
Exclusive for Stockcircle Pro members
Sign up
$738.39
137.4% upside
Current Fair Value
137.4% upsideUndervalued by 137.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $242.70 Billion |
|---|---|
| Enterprise Value | $275.54 Billion |
| Dividend Yield | $10.97477 (3.73507893723527%) |
| Earnings per Share | $10.32 |
| Beta | 0.17 |
| Outstanding Shares | 802,307,692 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 24.96 |
|---|---|
| PEG | -202.63 |
| Price to Sales | 2.43 |
| Price to Book Ratio | 6.91 |
| Enterprise Value to Revenue | 2.66 |
| Enterprise Value to EBIT | 9.35 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 1.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Roche Holding AG
CEO: Severin Schwan Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...